The community pharmacy bodies, along with England's largest pharmacy chains, have urged the Prime Minister, Rishi Sunak to resolve fund and workforce crisis
in the sector.
In the joint letter the Chief Executives of Association of Independent Multiple Pharmacies (AIMp), Company Chemists' Association (CCA), National Pharmacy Association
(NPA) and Pharmaceutical Services Negotiating Committee (PSNC), along with Boots, Lloydspharmacy, Well and Rowlands Pharmacy, said they are pleased to see Government
now recognising the key role that community pharmacy' could have in alleviating the strain on other NHS services.
However, the associations also warn that although the sector is ready to support, 'this will not be possible unless pharmacy is properly funded.'
Janet Morrison, PSNC Chief Executive, said: "The Prime Minister should also know that community pharmacies are also facing a crisis. They need sustainable investment,
urgently, if we are to avoid devasting consequences for pharmacies and for their patients."
The letter calls on Government to help pharmacy to resolve the funding, workforce and capacity issues engulfing the sector. It said: "Community pharmacies are in
crisis and after 7 years of 30% funding cuts have reached their limit."
A survey of over six thousands pharmacies has revealed that the community pharmacy sector is buckling under growing cost and capacity pressures.
The survey conducted by the Pharmaceutical Services Negotiating Committee, which also involved two thousand community pharmacy confirms, rising costs, patient
demand and
medicine supply issues continue to grip the sector.
PSNC's 2023 Pharmacy Pressures Survey, run as a follow up to the 2022 pressures survey, provides clear comparative data showing the worsening situation across
the sector.
Govt must act now
The result of the survey indeed paints a bleak picture for community pharmacies and it is clear that without urgent action from government and the NHS this will
only get worse: more community pharmacies will either be forced to reduce the number of services they provide or, in the worst-case scenario, will be left with
no option but to close their doors for good.
The PSNC has urged the government to act now "to save our pharmacies, before it is too late for patients, the public, and the rest of the NHS".
"This year's survey clearly shows that community pharmacies are buckling under growing cost and capacity pressures," said PSNC Chief Executive Janet Morrison.
With the Pharmacy First services scheduled for launch end of this month, legislators explored the potential of community pharmacies to offer specific
diagnostic and treatment services in the second public evidence session of pharmacy inquiry this week (January 16).
The new service, which will enable pharmacists to offer advice and prescribe treatment for seven minor ailments, is expected to alleviate the pressure on the
NHS, reduce GP workload, and cut waiting lists.
But MPs and healthcare leaders also acknowledged that there's hesitancy and the mindset of 'GP first, not Pharmacy First' among members of the public.
"We must accept that many patients are used to seeing their GP as their first port of call for many health conditions. Pharmacy First is welcome, but there are
going to be some restrictions on how quickly some patients will want to take up some of those services, rather than seeing their GP," said William Pett, Head
of Policy, Public Affairs and Research, Healthwatch England.
The tripartite negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 - Year 4 of the five-year CPCF deal - have now begun, the Pharmaceutical Services Negotiating Committee (PSNC) said.
The discussions, beginning ahead of the start of the financial year, are taking place between the PSNC and the Department of Health and Social Care (DHSC) and the NHS England and NHS Improvement (NHSE&I).
It will cover issues related to service, funding and other arrangements for pharmacies in 2022/23, in line with the five-year CPCF deal.
The three entities will also discuss the progress made to date, which has been partly impacted by the Covid-19 pandemic, and the recent joint Annual Review process, where PSNC raised serious concerns around the available capacity within community pharmacy.
The fusion of the unique in-depth understanding of medicines by pharmacists together with the competence to prescribe offers will improve access to care and
increase capacity in the health system, said the Royal Pharmaceutical Society (RPS) Director for England Ravi Sharma to Parliament at the Health and Social Care
Select Committee's inquiry on workforce on Monday (May 23).
However, he also stated that a new workforce strategy must support and harness the skills of pharmacist independent prescribers in clinical care with investment
in training, both for new and existing workforce; access to supervisors; protected learning and development time; and commissioning of services to make best use of
independent prescribers across care settings, supported by appropriate prescribing budgets in community pharmacy.
"We're about to see new generation of pharmacists independent prescribers that will make a huge difference to the clinical role of pharmacists to support patient care, but this must be underpinned by protected learning time and a more ambitious approach to commissioning new services to use their skills," Ravi said.
He spoke to MPs in Parliament at the Health and Social Care Select Committee's inquiry on workforce, highlighting the vital contribution of pharmacy teams during
the pandemic and called for action to support the current and future workforce.
Some of the key issues highlighted in the parliament included, the risk of burnout and the need to help boost staff retention; staff wellbeing, including a zero tolerance of abuse from the public; the importance of professional development and protected learning time to enhance patient care and support rewarding careers; the potential of new pharmacist independent prescribers and the need for investment in the current workforce and the need for better workforce data and a pharmacy workforce strategy.
Jeremy Meader has resigned as managing director of Numark after five years on the job, and having lead the wider PHOENIX group's sales and marketing teams for
about eight years.
A press release issued on Wednesday (February 1) said Mr Meader "has decided to leave the business to pursue his career outside of the PHOENIX group", the owner of
Numark.
It said: "PHOENIX thanks Jeremy for his commitment and dedication over the years and wishes him all the best for his professional and private future."
Previous to joining PHOENIX, Mr Meader was head of sales at Alliance Healthcare, a role he took up in 2012 after serving GSK's Consumer Healthcare division for over
13 years in various capacity.
Titan PMR has been accredited by the NHS to provide electronic prescription services (EPS) to dispensing doctors.
Over 1,000 of these doctors, who provide a vital service to almost 10 million people in rural communities, can now offer their patients the same level of benefits
and efficiencies that electronic prescriptions and Titan PMR have brought to pharmacies around the UK.
These features will also increase efficiency for dispensing doctors, who will reduce dispensing errors and improve organisation, increasing their capacity while
enjoying the ability to integrate with other technologies.
After a full year of testing, including six months of compliance testing at a practice in Cumbria, the new accreditation for Titan also has potential to help the
NHS fulfil its target of all prescriptions being issued electronically.
Currently written paper prescriptions from dispensing doctors account for around seven per cent of the total prescriptions in England - around 6.5 million each month.
"Until now dispensing doctor surgeries have basically been in the digital dark ages when it comes to dispensing medicines," said Tariq Muhammad, a tech entrepreneur
and CEO of Bristol-based Invatech Health, which developed Titan PMR.
Being able to access high-quality healthcare at the times you need it most is vital. Regardless of whether this is a simple check-up, a medical review or
complex surgery, having a suitable healthcare package designed according to your medical needs will be beneficial in the long run.
The NHS has recently come under significant strain. Factors such as an increase in the number of patients, reduced funding and increased life expectancy have led to
long waiting times and limited treatments.
As a result, more individuals are now seeking private healthcare which, while it may be more expensive, offers faster and more effective treatment. Here we'll discuss
some of the main benefits of private healthcare and why it is becoming the ideal choice for healthcare in 2023.
Reduced waiting times
One of the main issues faced by the NHS is waiting times, with some patients being made to wait up to a year for routine hospital care. Currently, ambulance services
and A&E units are under unprecedented pressure and it is estimated that hundreds of deaths each week are associated with admission delays.
Understaffing has been a chronic issue in recent years in the NHS and is a major threat to the welfare of patients. This has been one of the major concerns that has
led to nurses and ambulance staff taking strike action. As nurses and hospital workers are put under higher strain, they are more likely to make mistakes, which
could well lead to patients coming into harm and making a claim.
Opting for private healthcare guarantees that you are able to access your appointments, surgeries and treatments much quicker, with some flexibility offered to align
with your lifestyle. The capacity to bypass the painfully long waiting times ensures you receive the necessary medical attention much sooner and could prevent the
emergence of other health complications.
The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Dekra to certify medical devices in the UK.
Dekra Certification UK has joined the three current UK approved bodies, increasing the UK's capacity to process conformity assessments for medical devices to ensure
safe and effective devices reach the UK public.
An approved body is an organisation that has been designated by the MHRA to assess whether manufacturers and their medical devices meet the requirements set out in
the UK Medical Devices Regulations 2002.
Following an appropriate assessment, the new approved body will issue relevant certification allowing manufacturers to place a UKCA marking on their products before
putting them on the market.
Dr Laura Squire, chief healthcare quality and access officer at the MHRA, said: "This is a major milestone in our mission to ensure patients across the UK have access
to the high-quality medical devices they need to protect their health.